NCT06723080

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 480 (estimated)
• Sponsor: Jiangsu vcare pharmaceutical technology co., LTD · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study

Conditions

• Moderate to Severe Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	VC005 low dose group	VC005 low dose group repeat administration
DRUG	VC005 high dose group	VC005 high dose group repeat administration
DRUG	VC005 Placebo group	VC005 Placebo group repeat administration

Timeline

• Start date: 2024-12-30
• Primary completion: 2027-08-30
• Completion: 2027-08-30
• First posted: 2024-12-09
• Last updated: 2025-02-11

Locations

1 site across 1 country: China